BioNTech Investor Presentation Deck

Infectious Disease Pipeline: 4 mRNA Vaccine Trial Starts Expected in 2022 20 5 mRNA vaccines partnered w/Pfizer 10+ other infectious disease programs Indication COVID-191 COVID-191 Influenza (mod mRNA)¹ Influenza (sa mRNA)¹ Shingles¹ HSV 2² Tuberculosis ³ Malaria HIV 3 Additional mRNA vaccine programs ² Precision antibacterials Product candidate Pre-clinical Phase 1 BNT 162b2 BNT162b5 BNT 161 Un-named program Un-named program BNT 163 BNT164 BNT165 Un-named program Un-named programs Un-named programs Phase 2 Commercial Milestones 2022 Multiple updates Phase 2 started in July 2022 Data updated in July 2022 Start Phase 1: 2H 2022 Start Phase 1: 2H 2022 Start Phase 1: 2H 2022 / early 2023 Start Phase 1: 2H 2022 / early 2023 ¹Collaboration with Pfizer; 2University of Pennsylvania collaboration; ³Collaboration with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where BMG holds distribution rights. BIONTECH

View entire presentation